Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis.

Autor:	Alkodaymi MS; Department of Family & Community Medicine, Alfaisal University, Riyadh, Saudi Arabia., Omrani OA; The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom; Barts and the London School of Medicine and Dentistry, Queen Mary University, London, United Kingdom., Fawzy NA; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Shaar BA; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Almamlouk R; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Riaz M; Center for Trial Research, School of Medicine, Cardiff University, United Kingdom., Obeidat M; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Obeidat Y; UMass Chan Medical School-Baystate, Springfield, MA, USA., Gerberi D; Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA., Taha RM; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Kashour Z; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Kashour T; Department of Cardiac Sciences, King Fahad Cardiac Center, King Saud University Medical City, Riyadh, Saudi Arabia., Berbari EF; Infectious Diseases Section, Department of Medical Specialties King Fahad Medical City, Riyadh, Saudi Arabia., Alkattan K; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Tleyjeh IM; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Infectious Diseases Section, Department of Medical Specialties King Fahad Medical City, Riyadh, Saudi Arabia; Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Department of Epidemiology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. Electronic address: Tleyjeh.Imad@mayo.edu.
Jazyk:	angličtina
Zdroj:	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2022 May; Vol. 28 (5), pp. 657-666. Date of Electronic Publication: 2022 Feb 03.
DOI:	10.1016/j.cmi.2022.01.014
Abstrakt:	Background: Post-acute coronavirus 2019 (COVID-19) syndrome is now recognized as a complex systemic disease that is associated with substantial morbidity. Objectives: To estimate the prevalence of persistent symptoms and signs at least 12 weeks after acute COVID-19 at different follow-up periods. Data Sources: Searches were conducted up to October 2021 in Ovid Embase, Ovid Medline, and PubMed. Study Eligibility Criteria, Participants and Interventions: Articles in English that reported the prevalence of persistent symptoms among individuals with confirmed severe acute respiratory syndrome coronavirus 2 infection and included at least 50 patients with a follow-up of at least 12 weeks after acute illness. Methods: Random-effect meta-analysis was performed to produce a pooled prevalence for each symptom at four different follow-up time intervals. Between-study heterogeneity was evaluated using the I2 statistic and was explored via meta-regression, considering several a priori study-level variables. Risk of bias was assessed using the Joanna Briggs Institute tool and the Newcastle-Ottawa Scale for prevalence studies and comparative studies, respectively. Results: After screening 3209 studies, a total of 63 studies were eligible, with a total COVID-19 population of 257 348. The most commonly reported symptoms were fatigue, dyspnea, sleep disorder, and difficulty concentrating (32%, 25%, 24%, and 22%, respectively, at 3- to <6-month follow-up); effort intolerance, fatigue, sleep disorder, and dyspnea (45%, 36%, 29%, and 25%, respectively, at 6- to <9-month follow-up); fatigue (37%) and dyspnea (21%) at 9 to <12 months; and fatigue, dyspnea, sleep disorder, and myalgia (41%, 31%, 30%, and 22%, respectively, at >12-month follow-up). There was substantial between-study heterogeneity for all reported symptom prevalences. Meta-regressions identified statistically significant effect modifiers: world region, male sex, diabetes mellitus, disease severity, and overall study quality score. Five of six studies including a comparator group consisting of COVID-19-negative cases observed significant adjusted associations between COVID-19 and several long-term symptoms. Conclusions: This systematic review found that a large proportion of patients experience post-acute COVID-19 syndrome 3 to 12 months after recovery from the acute phase of COVID-19. However, available studies of post-acute COVID-19 syndrome are highly heterogeneous. Future studies need to have appropriate comparator groups, standardized symptom definitions and measurements, and longer follow-up. (Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu